Ocula AI Engine™
Purpose built from the ground up by an experienced team of technologists, our proprietary engine fuses deep machine learning and advanced computer vision to craft brand new, world leading medical diagnostic support technology.
Breakthrough NeuroTechnology.
Ocula AI™ delivers objective point-of-care neurological assessment technology using cutting edge artificial intelligence.
Modules
Our bleeding edge, proprietary Ocula AI™ technology provides point-of-care assessments for a variety of presentation contexts.
Concussion
Immediate, on-the-spot diagnostic support for head trauma impact victims of all ages in sports, accidents, dynamic work environments, and more.
Impairment
Instantly identify neurological impairment from drugs, alcohol, over-tiredness, and more.
Recovery / Decline
Track and project concussion recovery rate or rate of decline (including possible early onset indicators) of neurological disorders.
Audience
Our point-of-care assessment tool is designed to cater for a wide variety of use cases.
The current version of the tool is designed specifically for medical professionals that regularly use ocular assessments including (but not limited to) doctors, neurologists, physiotherapists, chiropractors, etc.
We are opening access to an invite only private beta of the solution later this year - request an invite below.
Professionals
An advanced version of the tool for medical professionals.
Organisations
Platform to centralise and track longitudinal assessment data.
Researchers
Research platform with access to a global de-identified dataset.
Early access
We're opening up early access to medical professionals interested in exploring objective, point-of-care ocular assessments in their daily practice.
Frequently Asked Questions
Over the past three years we've been conducting continuous research and development driving new breakthrough technology. The company is still operating in stealth mode so it's understandable that you may have a few questions. If your answer isn't here, reach out to us directly.
What exactly am I signing up to access?
The short answer is at this stage we can't be any more explicit than we have been so far. Given the sensitive nature of our world leading breakthrough technology we have to keep everything under wraps for a little longer.
Who is behind Ocula AI™?
Ocula is a wholly owned subsidiary of Equinox Ventures - a private, Australia-based, bootstrapped venture studio run by Ben Richardson and Brendan White. Other ventures in the portfolio include Labflow and Comply Group.
Are you currently looking for investors?
The Research & Development for Ocula is currently well funded. In mid to late 2023 we will begin conversations for raising external capital to fuel growth and new market entry to allow us to make the the most our first mover advantage.
What about privacy and cyber security?
We have the correct expertise in place to meet the highest privacy and data security requirements with ease. We also have privacy and cyber security enhancement packs to support government and military standards (e.g. IRAP).
When will the community version be available?
Most likely sometime in 2024. That said, we'll be rolling out our solution for organisations in 2023 which is likely to alsoencompass community organisations and non-profits as well.